Search

Page Title

Clinical Trial Finder

Back to the Clinical Trial Finder

Anti-Infective Completed with Results

Long-term Safety Study of Aztreonam Lysinate in CF Patients with P. aeruginosa (AIR-CF3) (CP-AI-006)

The purpose of this study was to evaluate the safety of an inhaled antibiotic, aztreonam, in CF patients who have respiratory infections caused by the Pseudomonas aeruginosa bacteria.

Reducing damage from chronic Pseudomonas aeruginosa lung infections is vital to maintaining the best health in people with CF. Aztreonam has been successfully used to treat CF lung infections and other diseases in a formulation for intravenous or intramuscular injection.

Eligibility

See other primary eligibility criteria for more information.

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 75%

For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.

Other Primary Eligibility Criteria

To be included in this open-label extension study, a subject must have completed either Air-CF1 or Air-CF2.

Study Results

  • What We Learned:

  • Primary Findings:

    Effectiveness:

    This open-label study included 274 patients with CF (Age >=6) with pulmonary P. aeruginosa and who had completed one of two previous double-blind studies (AIR CF 1 or AIR CF 2). Patients received AZLI either twice daily or three times daily for nine cycles of 28 days on-drug followed by 28 days off drug. Patients who received AZLI three times a day had greater improvement in FEV1 and in patient reported outcomes (Cystic Fibrosis Questionnaire – Revised).

     

    Median time to hospitalization was also longer in patients treated three times daily compared with patients dosed twice daily.

    Safety:

    The most common adverse events were those related to respiratory conditions consistent with CF. The two most commonly reported AEs were cough and productive cough. AEs were more frequently reported during the off-drug periods than during the on-drug periods. There was no evidence that the incidence of any common AE increased with repeated exposure.

  • Citation:

    Pediatr Pulmonol 2010;45(11):1121-34

For current information about the overall development status of this drug, please check the Drug Development Pipeline.

Study Design

  • Study Type: ?more info

    Interventional

  • Randomized Study: ?more info

    No

  • Placebo Controlled: ?more info

    No

  • Length of Participation:

    6 months

  • Number of Study Visits:

    6

Additional Information

Eligibility

See other primary eligibility criteria for more information.

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 75%

  • Pseudomonas Status:

    Positive Respiratory Cultures Required

For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.

Other Primary Eligibility Criteria

To be included in this open-label extension study, a subject must have completed either Air-CF1 or Air-CF2.

CONTACT THE CLINICAL TRIAL NAVIGATOR

Get personalized assistance and answers to your clinical trial questions.

Learn More

Sign up for clinical trial alerts

Get email updates about clinical trials that matter to you.

Check the Drug Development Pipeline

We’re attacking CF from every angle. Learn about the status of CF drugs in development.

Learn More